Company intelligence / Profile preview
AceLink Therapeutics
Newark, California, United Statesacelinktherapeutics.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Other
01
Overview
AceLink's lead candidate AL01211 has shown promising interim Phase 2 results in treatment-naïve classic male Fabry disease patients. The drug was generally safe and well-tolerated, with a 30mg once daily dose reducing GL3 levels by 50%, while a 60mg dose showed faster and greater reduction. Preliminary data suggests AL01211 stabilizes Fabry disease symptoms including eGFR and proteinuria levels, with positive trends in pain reduction, quality of life, and global disease symptom assessment. Topline data from this Phase 2 trial is expected in Q3 2025.
- Therapeutic areas
- Rare DiseasesNeurologyNephrology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on AceLink Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AceLink Therapeutics.